Bacterial colonization of tumors drives immune activation and checkpoint blockade efficacy

The tumor microenvironment (TME), which heavily influences immune checkpoint blockade (ICB) efficacy, is shaped by host-microbe interactions. Endogenous intratumoral bacteria have been implicated in efficacy of ICB, such as anti-PD-1 (aPD-1), however, their role in modulating the TME, and whether these TME interactions are represented in murine tumor models, remains unknown. Using 16S rRNA qPCR, sequencing, and culture-based methods on multiple murine tumor models, we identified intratumoral microbiota in MCA-205 tumors but not in MOC1 tumors, underscoring the role of tumor-intrinsic factors in shaping microbial colonization. In MCA-205 tumors, intratumoral microbiota increased dendritic cell (DC) maturation and CD8+ T cell infiltration and activation, boosting ICB therapeutic efficacy. Specific depletion of only the intratumoral microbiota abrogated these effects. We found these bacteria-dependent effects were not due to canonical TLR signaling, as aPD-1 efficacy was not reduced by blocking TLR signaling through MyD88 depletion or enhanced by adding E. coli into the TME. This suggests that specific microbial species or communities, rather than bacterial colonization alone, are required to modulate antitumor immunity. These results reveal that intratumoral microbiota, when present, can dictate ICB efficacy, highlighting the importance of understanding this variable in murine experiments aiming to optimize cancer immunotherapy.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-02-12
DOI
https://doi.org/10.1038/s41598-026-39758-z
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Bacterial colonization of tumors drives immune activation and checkpoint blockade efficacy

Karen S. Sfanos, Melissa J. Kasiewicz, William L. Redmond, Grace Helen McGee et al.
Scientific Reports
Cancer Immunotherapy and Biomarkers
article

Bacterial colonization of tumors drives immune activation and checkpoint blockade efficacy

Karen S. Sfanos, Melissa J. Kasiewicz, William L. Redmond, Grace Helen McGee, Annah S. Rolig, Joanna Pucilowska, Tahereh Ziglari, Noah D. Simons, Kenna Kolbaba
article en

Abstract

The tumor microenvironment (TME), which heavily influences immune checkpoint blockade (ICB) efficacy, is shaped by host-microbe interactions. Endogenous intratumoral bacteria have been implicated in efficacy of ICB, such as anti-PD-1 (aPD-1), however, their role in modulating the TME, and whether these TME interactions are represented in murine tumor models, remains unknown. Using 16S rRNA qPCR, sequencing, and culture-based methods on multiple murine tumor models, we identified intratumoral microbiota in MCA-205 tumors but not in MOC1 tumors, underscoring the role of tumor-intrinsic factors in shaping microbial colonization. In MCA-205 tumors, intratumoral microbiota increased dendritic cell (DC) maturation and CD8+ T cell infiltration and activation, boosting ICB therapeutic efficacy. Specific depletion of only the intratumoral microbiota abrogated these effects. We found these bacteria-dependent effects were not due to canonical TLR signaling, as aPD-1 efficacy was not reduced by blocking TLR signaling through MyD88 depletion or enhanced by adding E. coli into the TME. This suggests that specific microbial species or communities, rather than bacterial colonization alone, are required to modulate antitumor immunity. These results reveal that intratumoral microbiota, when present, can dictate ICB efficacy, highlighting the importance of understanding this variable in murine experiments aiming to optimize cancer immunotherapy.

Scientific ReportsVol. 16(1)
Providence St. Vincent Medical Center (US), Johns Hopkins University (US), Oregon Health & Science University (US), University of Utah (US), Johns Hopkins Medicine (US), Providence Portland Medical Center (US), Sidney Kimmel Comprehensive Cancer Center (US)
Bristol-Myers Squibb, National Institutes of Health
Openalex Percentile: Top 58%
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.